Koji Iinuma

467 total citations
69 papers, 287 citations indexed

About

Koji Iinuma is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Koji Iinuma has authored 69 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 26 papers in Surgery and 18 papers in Oncology. Recurrent topics in Koji Iinuma's work include Prostate Cancer Treatment and Research (22 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Bladder and Urothelial Cancer Treatments (19 papers). Koji Iinuma is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Bladder and Urothelial Cancer Treatments (19 papers). Koji Iinuma collaborates with scholars based in Japan. Koji Iinuma's co-authors include Takuya Koie, Keita Nakane, Daiki Kato, Manabu Takai, Makoto Kawase, Kosuke Mizutani, Takashi Ishida, Taku Kato, Tomohiro Tsuchiya and Yuriko Katsushima and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and Urology.

In The Last Decade

Koji Iinuma

60 papers receiving 284 citations

Peers

Countries citing papers authored by Koji Iinuma

Since Specialization

Citations

This map shows the geographic impact of Koji Iinuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Iinuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Iinuma more than expected).

Fields of papers citing papers by Koji Iinuma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koji Iinuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Iinuma. The network helps show where Koji Iinuma may publish in the future.

Co-authorship network of co-authors of Koji Iinuma

This figure shows the co-authorship network connecting the top 25 collaborators of Koji Iinuma. A scholar is included among the top collaborators of Koji Iinuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Iinuma. Koji Iinuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low GCNT2/I-Branching Glycan Expression Is Associated with Bladder Cancer Aggressiveness 2025 ·Biomedicines ·Yuki Tobisawa, Keita Nakane, Takuya Koie, (unknown), (unknown), (unknown), (unknown), Makoto Kawase, Koji Iinuma	0
2	Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review 2024 ·Journal of Clinical Medicine ·Makoto Kawase, Keita Nakane, Koji Iinuma, (unknown), (unknown), (unknown), Yuki Tobisawa, Takuya Koie	1
3	Impact of Robotic-Assisted Partial Nephrectomy with Single Layer versus Double Layer Renorrhaphy on Postoperative Renal Function 2024 ·Current Oncology ·Hiroyuki Ito, Keita Nakane, (unknown), Makoto Kawase, Daiki Kato, Koji Iinuma, Kenichiro Ishida, (unknown), (unknown), Yuki Tobisawa, (unknown), Takuya Koie	2
4	Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan 2024 ·Current Oncology ·(unknown), Koji Iinuma, Kei Kawada, Takashi Ishida, (unknown), (unknown), Makoto Kawase, (unknown), Keita Nakane, Yuki Tobisawa, Takuya Koie	4
5	Temporary Tumor Shrinkage Following Enfortumab Vedotin Therapy for Metastatic Urothelial Carcinoma After Radical Cystectomy With Neoadjuvant Chemotherapy: A Case Report 2023 ·Cureus ·(unknown), Daiki Kato, Koji Iinuma, Keita Nakane, Takuya Koie	2
6	Seed Density as a New Predictive Index of Seed Migration in Brachytherapy for Prostate Cancer Using Iodine-125 Loose Seed 2023 ·Current Oncology ·Takahiro Yamaguchi, Masayuki Matsuo, (unknown), Yoshifumi Noda, Chiyoko Makita, Fuminori Hyodo, Koji Iinuma, Masahiro Nakano, Takuya Koie, Hidekazu Tanaka	0
7	The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study 2023 ·Cancers ·Koji Iinuma, (unknown), Koji Kameyama, (unknown), Kei Kawada, Takashi Ishida, (unknown), (unknown), (unknown), (unknown), Makoto Kawase, Shinichi Takeuchi, (unknown), Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie	8
8	Endoscopic combined intrarenal surgery for renal allograft lithiasis using “sheath-connection technique”: A case report 2023 ·Urology Case Reports ·(unknown), Keita Nakane, Makoto Kawase, Koji Iinuma, (unknown), Takuya Koie	1
9	Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study 2022 ·Biomedicines ·Koji Iinuma, (unknown), Koji Kameyama, (unknown), Kei Kawada, Takashi Ishida, (unknown), (unknown), (unknown), Makoto Kawase, Shinichi Takeuchi, (unknown), Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie	2
10	Clinical Predictors of Grade Group Upgrading for Radical Prostatectomy Specimens Compared to Those of Preoperative Needle Biopsy Specimens 2022 ·Diagnostics ·(unknown), Chiemi Saigo, (unknown), Natsuko Suzui, Tatsuhiko Miyazaki, Shinichi Takeuchi, Makoto Kawase, (unknown), Daiki Kato, Manabu Takai, Koji Iinuma, Keita Nakane, Tamotsu Takeuchi, Takuya Koie	0
11	Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study 2022 ·Biomedicines ·(unknown), Keita Nakane, (unknown), (unknown), (unknown), Takashi Ishida, (unknown), (unknown), Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, (unknown), Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, (unknown), Takuya Koie	6
12	The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma 2022 ·Biomedicines ·(unknown), Keita Nakane, (unknown), (unknown), (unknown), Takashi Ishida, (unknown), (unknown), Hiroki Ito, Shinichi Takeuchi, Makoto Kawase, (unknown), Daiki Kato, Manabu Takai, Koji Iinuma, Shigeaki Yokoi, (unknown), Takuya Koie	11
13	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab 2021 ·Journal of Clinical Medicine ·Koji Iinuma, (unknown), Kei Kawada, Shota Fujimoto, Takashi Ishida, (unknown), (unknown), Hiroki Ito, Makoto Kawase, (unknown), (unknown), Daiki Kato, Manabu Takai, Keita Nakane, Koji Kameyama, Takuya Koie	27
14	Leptomeningeal Carcinomatosis in Urothelial Carcinoma of the Urinary Bladder: A Report of a Patient with a Fulminant Course Who Died of Cancer after Definitive Therapies 2021 ·SHILAP Revista de lepidopterología ·(unknown), Makoto Kawase, Daiki Kato, Manabu Takai, Koji Iinuma, Kengo Horie, Keita Nakane, Natsuko Suzui, Tatsuhiko Miyazaki, Takuya Koie	2
15	Solitary Fibrous Tumor of the Prostate: A Case Report and Literature Review 2021 ·Medicina ·(unknown), Daiki Kato, Keita Nakane, (unknown), Manabu Takai, Koji Iinuma, Chiemi Saigo, Tatsuhiko Miyazaki, Takuya Koie	5
16	A Case of Localized Prostate Cancer Associated with Polymyalgia Rheumatica with Marked Symptomatic Improvement after Robot-Assisted Radical Prostatectomy 2021 ·SHILAP Revista de lepidopterología ·Makoto Kawase, Keita Nakane, (unknown), (unknown), (unknown), (unknown), (unknown), Shinichi Takeuchi, Daiki Kato, Manabu Takai, Koji Iinuma, (unknown), Chiemi Saigo, Tatsuhiko Miyazaki, Hiroyuki Morita, Takuya Koie	1
17	Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer 2021 ·The Scientific World JOURNAL ·(unknown), Manabu Takai, Koji Iinuma, Shota Fujimoto, Masahiro Nakano, Takashi Ishida, (unknown), Masayoshi Tamaki, (unknown), Hisao Komeda, Yoshito Takahashi, Takuya Koie	2
18	Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study 2021 ·Current Oncology ·Koji Iinuma, Koji Kameyama, Kei Kawada, Shota Fujimoto, (unknown), (unknown), Hiroki Ito, Takashi Ishida, Makoto Kawase, (unknown), (unknown), Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie	15
19	A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab 2021 ·Cancer Reports ·(unknown), Keita Nakane, (unknown), Koji Iinuma, Natsuko Suzui, Tatsuhiko Miyazaki, Takuya Koie	3
20	Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration‐resistant prostate cancer: A local experience of a multicenter retrospective study 2020 ·Asia-Pacific Journal of Clinical Oncology ·Manabu Takai, (unknown), Masahiro Nakano, Shota Fujimoto, Koji Iinuma, Takashi Ishida, (unknown), Masayoshi Tamaki, (unknown), Yoshito Takahashi, Hisao Komeda, Takuya Koie	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact